Xiaflex 0.9 MG vials
Ended Awarded
- Contract number
- SPE2DB25FD4YX
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,358
Award facts
- Contract value 100% obligated
- $16,357.68 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $16,357.68 on September 26, 2025, for the supply of Xiaflex 0.9 mg vials. This firm fixed-price delivery order, with an ultimate completion date of October 20, 2025, was issued by the Defense Logistics Agency under its existing Indefinite Delivery Contract (IDC) arrangement. The contract carries no set-aside designation, and the place of performance is located in Park Ridge, Illinois. Xiaflex is a pharmaceutical product used in medical treatment, and this delivery order represents one of numerous pharmaceutical product acquisitions the DLA regularly places through its established vendor relationships.
This award exemplifies DMS Pharmaceutical Group's role as a critical supplier within the federal pharmaceutical supply chain, particularly for Department of Defense healthcare facilities. The vendor holds a significant single-award IDC with the DLA under the SPE2DB program valued at $499,999,999 and valid through November 2026, which enables the agency to issue firm fixed-price delivery orders for comprehensive pharmaceutical products supporting military health facility needs. DMS Pharmaceutical Group's consistent success in securing contracts with the DLA without set-aside designations demonstrates its competitive positioning and ability to supply diverse pharmaceutical items ranging from prescription medications to specialty products across multiple therapeutic categories.
Quick answers
Who was awarded contract SPE2DB25FD4YX?
SPE2DB25FD4YX was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 26, 2025.
How much is contract SPE2DB25FD4YX worth?
The government has obligated $16,358 on SPE2DB25FD4YX.
Is contract SPE2DB25FD4YX an order under another contract?
Yes. SPE2DB25FD4YX is a delivery order under SPE2DB20D9214, an indefinite delivery contract.
Was contract SPE2DB25FD4YX competed?
The extent of competition for SPE2DB25FD4YX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award